ROYCE & ASSOCIATES LP - HALOZYME THERAPEUTICS INC ownership

HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 124 filers reported holding HALOZYME THERAPEUTICS INC in Q3 2014. The put-call ratio across all filers is 0.57 and the average weighting 0.2%.

Quarter-by-quarter ownership
ROYCE & ASSOCIATES LP ownership history of HALOZYME THERAPEUTICS INC
ValueSharesWeighting
Q1 2023$1,718,550
-68.5%
45,000
-53.1%
0.02%
-70.2%
Q4 2022$5,462,400
+43.9%
96,0000.0%0.06%
+32.6%
Q3 2022$3,796,000
-10.1%
96,0000.0%0.04%0.0%
Q2 2022$4,224,000
+231.0%
96,000
+200.0%
0.04%
+290.9%
Q1 2022$1,276,000
+10533.3%
32,000
+2566.7%
0.01%
Q2 2014$12,000
-98.6%
1,200
-98.2%
0.00%
-100.0%
Q1 2014$839,000
-50.3%
66,075
-41.4%
0.00%
-60.0%
Q4 2013$1,689,000
+3.6%
112,697
-23.7%
0.01%0.0%
Q3 2013$1,631,000
+145.6%
147,697
+76.6%
0.01%
+150.0%
Q2 2013$664,00083,6220.00%
Other shareholders
HALOZYME THERAPEUTICS INC shareholders Q3 2014
NameSharesValueWeighting ↓
Third Security, LLC 1,129,551$47,091,0006.38%
First Light Asset Management, LLC 2,011,350$83,853,0005.56%
TRAN CAPITAL MANAGEMENT, L.P. 1,353,208$56,415,0005.03%
SNYDER CAPITAL MANAGEMENT L P 2,920,860$121,771,0003.50%
DOHENY ASSET MANAGEMENT /CA 120,028$5,004,0003.39%
SILVERARC CAPITAL MANAGEMENT, LLC 104,945$4,375,0002.39%
Redwood Investments, LLC 542,764$22,628,0001.99%
Kent Lake Capital LLC 85,000$3,544,0001.44%
Lisanti Capital Growth, LLC 263,460$10,984,0001.41%
Bellevue Group AG 3,011,966$125,569,0001.33%
View complete list of HALOZYME THERAPEUTICS INC shareholders